Jiejie Xu
YOU?
Author Swipe
View article: Data from ARID1A Loss plus CD8<sup>+</sup> T-Cell Infiltration Associate with Favorable Clinical Outcomes in Urothelial Carcinoma
Data from ARID1A Loss plus CD8<sup>+</sup> T-Cell Infiltration Associate with Favorable Clinical Outcomes in Urothelial Carcinoma Open
Purpose:ARID1A, encoding a component of the switch/sucrose nonfermentable complex, is frequently mutated in urothelial carcinoma. However, its specific impacts on clinical outcomes and CD8+ T-cell functions in urothelial carcinoma remain p…
View article: Supplementary Table S1 from ARID1A Loss plus CD8<sup>+</sup> T-Cell Infiltration Associate with Favorable Clinical Outcomes in Urothelial Carcinoma
Supplementary Table S1 from ARID1A Loss plus CD8<sup>+</sup> T-Cell Infiltration Associate with Favorable Clinical Outcomes in Urothelial Carcinoma Open
Details of immunohistochemistry antibodies.
View article: Supplementary Figure S4 from ARID1A Loss plus CD8<sup>+</sup> T-Cell Infiltration Associate with Favorable Clinical Outcomes in Urothelial Carcinoma
Supplementary Figure S4 from ARID1A Loss plus CD8<sup>+</sup> T-Cell Infiltration Associate with Favorable Clinical Outcomes in Urothelial Carcinoma Open
Association between ARID1A status and CD8+ T cell signature in the IMvigor210 cohort.
View article: Supplementary Figure S3 from ARID1A Loss plus CD8<sup>+</sup> T-Cell Infiltration Associate with Favorable Clinical Outcomes in Urothelial Carcinoma
Supplementary Figure S3 from ARID1A Loss plus CD8<sup>+</sup> T-Cell Infiltration Associate with Favorable Clinical Outcomes in Urothelial Carcinoma Open
Association between ARID1A status and TMB in UC.
View article: Supplementary Figure S1 from ARID1A Loss plus CD8<sup>+</sup> T-Cell Infiltration Associate with Favorable Clinical Outcomes in Urothelial Carcinoma
Supplementary Figure S1 from ARID1A Loss plus CD8<sup>+</sup> T-Cell Infiltration Associate with Favorable Clinical Outcomes in Urothelial Carcinoma Open
Enrollment, clinicopathological features and inclusion criteria for ZSHS, FUSCC, and Shanghai-sequencing cohorts.
View article: Supplementary Figure S2 from ARID1A Loss plus CD8<sup>+</sup> T-Cell Infiltration Associate with Favorable Clinical Outcomes in Urothelial Carcinoma
Supplementary Figure S2 from ARID1A Loss plus CD8<sup>+</sup> T-Cell Infiltration Associate with Favorable Clinical Outcomes in Urothelial Carcinoma Open
Representative IHC images of ARID1A and CD8+ T cells in UC.
View article: Supplementary Table S2 from ARID1A Loss plus CD8<sup>+</sup> T-Cell Infiltration Associate with Favorable Clinical Outcomes in Urothelial Carcinoma
Supplementary Table S2 from ARID1A Loss plus CD8<sup>+</sup> T-Cell Infiltration Associate with Favorable Clinical Outcomes in Urothelial Carcinoma Open
Sources and details of the utilized gene signatures.
View article: Supplementary Figure 10 from SPP1<sup>+</sup> Tumor-Associated Macrophages Drive Immunotherapy Resistance via CD8<sup>+</sup> T-cell Dysfunction in Clear-Cell Renal Cell Carcinoma
Supplementary Figure 10 from SPP1<sup>+</sup> Tumor-Associated Macrophages Drive Immunotherapy Resistance via CD8<sup>+</sup> T-cell Dysfunction in Clear-Cell Renal Cell Carcinoma Open
Supplementary Figure 10. Identification of TAMs through CyTOF.
View article: Data from SPP1<sup>+</sup> Tumor-Associated Macrophages Drive Immunotherapy Resistance via CD8<sup>+</sup> T-cell Dysfunction in Clear-Cell Renal Cell Carcinoma
Data from SPP1<sup>+</sup> Tumor-Associated Macrophages Drive Immunotherapy Resistance via CD8<sup>+</sup> T-cell Dysfunction in Clear-Cell Renal Cell Carcinoma Open
Tumor-associated macrophages (TAM) are key regulators of tumor immunity. With advances in single-cell analyses, secreted phosphoprotein 1 (SPP1)–positive TAMs have been observed across multiple tumor sites. However, their clinical relevanc…
View article: Supplementary Figure 6 from SPP1<sup>+</sup> Tumor-Associated Macrophages Drive Immunotherapy Resistance via CD8<sup>+</sup> T-cell Dysfunction in Clear-Cell Renal Cell Carcinoma
Supplementary Figure 6 from SPP1<sup>+</sup> Tumor-Associated Macrophages Drive Immunotherapy Resistance via CD8<sup>+</sup> T-cell Dysfunction in Clear-Cell Renal Cell Carcinoma Open
Supplementary Figure 6. Association between SPP1+ TAMs infiltration and PFS after immunotherapy in ccRCC.
View article: Supplementary Tables from SPP1<sup>+</sup> Tumor-Associated Macrophages Drive Immunotherapy Resistance via CD8<sup>+</sup> T-cell Dysfunction in Clear-Cell Renal Cell Carcinoma
Supplementary Tables from SPP1<sup>+</sup> Tumor-Associated Macrophages Drive Immunotherapy Resistance via CD8<sup>+</sup> T-cell Dysfunction in Clear-Cell Renal Cell Carcinoma Open
Supplementary table 1-9
View article: Supplementary Figure 8 from SPP1<sup>+</sup> Tumor-Associated Macrophages Drive Immunotherapy Resistance via CD8<sup>+</sup> T-cell Dysfunction in Clear-Cell Renal Cell Carcinoma
Supplementary Figure 8 from SPP1<sup>+</sup> Tumor-Associated Macrophages Drive Immunotherapy Resistance via CD8<sup>+</sup> T-cell Dysfunction in Clear-Cell Renal Cell Carcinoma Open
Supplementary Figure 8. SPP1+ TAMs infiltration is associated with worse prognosis in ccRCC.
View article: Supplementary Figure 7 from SPP1<sup>+</sup> Tumor-Associated Macrophages Drive Immunotherapy Resistance via CD8<sup>+</sup> T-cell Dysfunction in Clear-Cell Renal Cell Carcinoma
Supplementary Figure 7 from SPP1<sup>+</sup> Tumor-Associated Macrophages Drive Immunotherapy Resistance via CD8<sup>+</sup> T-cell Dysfunction in Clear-Cell Renal Cell Carcinoma Open
Supplementary Figure 7. Univariate Cox analysis of the correlation between SPP1+ TAMs infiltration and OS/PFS among ccRCC patients treated with immunotherapy.
View article: Supplementary Figure 17 from SPP1<sup>+</sup> Tumor-Associated Macrophages Drive Immunotherapy Resistance via CD8<sup>+</sup> T-cell Dysfunction in Clear-Cell Renal Cell Carcinoma
Supplementary Figure 17 from SPP1<sup>+</sup> Tumor-Associated Macrophages Drive Immunotherapy Resistance via CD8<sup>+</sup> T-cell Dysfunction in Clear-Cell Renal Cell Carcinoma Open
Supplementary Figure 17. SPP1+ TAMs infiltration correlates with BAP1 mutation in ccRCC.
View article: Supplementary Figure 18 from SPP1<sup>+</sup> Tumor-Associated Macrophages Drive Immunotherapy Resistance via CD8<sup>+</sup> T-cell Dysfunction in Clear-Cell Renal Cell Carcinoma
Supplementary Figure 18 from SPP1<sup>+</sup> Tumor-Associated Macrophages Drive Immunotherapy Resistance via CD8<sup>+</sup> T-cell Dysfunction in Clear-Cell Renal Cell Carcinoma Open
Supplementary Figure 18. Changes in the TME following SPP1 blockade.
View article: Supplementary Figure 5 from SPP1<sup>+</sup> Tumor-Associated Macrophages Drive Immunotherapy Resistance via CD8<sup>+</sup> T-cell Dysfunction in Clear-Cell Renal Cell Carcinoma
Supplementary Figure 5 from SPP1<sup>+</sup> Tumor-Associated Macrophages Drive Immunotherapy Resistance via CD8<sup>+</sup> T-cell Dysfunction in Clear-Cell Renal Cell Carcinoma Open
Supplementary Figure 5. Univariate logistic regression analysis of the correlation between SPP1+ TAMs infiltration and ORR/DCR among ccRCC patients treated with immunotherapy.
View article: Supplementary Figure 1 from SPP1<sup>+</sup> Tumor-Associated Macrophages Drive Immunotherapy Resistance via CD8<sup>+</sup> T-cell Dysfunction in Clear-Cell Renal Cell Carcinoma
Supplementary Figure 1 from SPP1<sup>+</sup> Tumor-Associated Macrophages Drive Immunotherapy Resistance via CD8<sup>+</sup> T-cell Dysfunction in Clear-Cell Renal Cell Carcinoma Open
Supplementary Figure 1. Flow chart of cohort selection.
View article: Supplementary Figure 2 from SPP1<sup>+</sup> Tumor-Associated Macrophages Drive Immunotherapy Resistance via CD8<sup>+</sup> T-cell Dysfunction in Clear-Cell Renal Cell Carcinoma
Supplementary Figure 2 from SPP1<sup>+</sup> Tumor-Associated Macrophages Drive Immunotherapy Resistance via CD8<sup>+</sup> T-cell Dysfunction in Clear-Cell Renal Cell Carcinoma Open
Supplementary Figure 2. Validation of SPP1+ TAMs signature.
View article: Supplementary Figure 12 from SPP1<sup>+</sup> Tumor-Associated Macrophages Drive Immunotherapy Resistance via CD8<sup>+</sup> T-cell Dysfunction in Clear-Cell Renal Cell Carcinoma
Supplementary Figure 12 from SPP1<sup>+</sup> Tumor-Associated Macrophages Drive Immunotherapy Resistance via CD8<sup>+</sup> T-cell Dysfunction in Clear-Cell Renal Cell Carcinoma Open
Supplementary Figure 12. Characterization of SPP1+ TAMs through flow cytometry.
View article: Supplementary Figure 15 from SPP1<sup>+</sup> Tumor-Associated Macrophages Drive Immunotherapy Resistance via CD8<sup>+</sup> T-cell Dysfunction in Clear-Cell Renal Cell Carcinoma
Supplementary Figure 15 from SPP1<sup>+</sup> Tumor-Associated Macrophages Drive Immunotherapy Resistance via CD8<sup>+</sup> T-cell Dysfunction in Clear-Cell Renal Cell Carcinoma Open
Supplementary Figure 15. Characterization of CD8+ T cells through flow cytometry.
View article: Supplementary Figure 16 from SPP1<sup>+</sup> Tumor-Associated Macrophages Drive Immunotherapy Resistance via CD8<sup>+</sup> T-cell Dysfunction in Clear-Cell Renal Cell Carcinoma
Supplementary Figure 16 from SPP1<sup>+</sup> Tumor-Associated Macrophages Drive Immunotherapy Resistance via CD8<sup>+</sup> T-cell Dysfunction in Clear-Cell Renal Cell Carcinoma Open
Supplementary Figure 16. Association between SPP1+ TAMs infiltration and main immune cells infiltration in ccRCC.
View article: Supplementary Figure 13 from SPP1<sup>+</sup> Tumor-Associated Macrophages Drive Immunotherapy Resistance via CD8<sup>+</sup> T-cell Dysfunction in Clear-Cell Renal Cell Carcinoma
Supplementary Figure 13 from SPP1<sup>+</sup> Tumor-Associated Macrophages Drive Immunotherapy Resistance via CD8<sup>+</sup> T-cell Dysfunction in Clear-Cell Renal Cell Carcinoma Open
Supplementary Figure 13. Identification of T cells through CyTOF.
View article: Supplementary Figure 19 from SPP1<sup>+</sup> Tumor-Associated Macrophages Drive Immunotherapy Resistance via CD8<sup>+</sup> T-cell Dysfunction in Clear-Cell Renal Cell Carcinoma
Supplementary Figure 19 from SPP1<sup>+</sup> Tumor-Associated Macrophages Drive Immunotherapy Resistance via CD8<sup>+</sup> T-cell Dysfunction in Clear-Cell Renal Cell Carcinoma Open
Supplementary Figure 19. Changes in CD8+ T cells following SPP1 blockade.
View article: Supplementary Figure 3 from SPP1<sup>+</sup> Tumor-Associated Macrophages Drive Immunotherapy Resistance via CD8<sup>+</sup> T-cell Dysfunction in Clear-Cell Renal Cell Carcinoma
Supplementary Figure 3 from SPP1<sup>+</sup> Tumor-Associated Macrophages Drive Immunotherapy Resistance via CD8<sup>+</sup> T-cell Dysfunction in Clear-Cell Renal Cell Carcinoma Open
Supplementary Figure 3. Characterization of TAMs and T cells in the ccRCC through CyTOF and flow cytometry.
View article: Supplementary Figure 4 from SPP1<sup>+</sup> Tumor-Associated Macrophages Drive Immunotherapy Resistance via CD8<sup>+</sup> T-cell Dysfunction in Clear-Cell Renal Cell Carcinoma
Supplementary Figure 4 from SPP1<sup>+</sup> Tumor-Associated Macrophages Drive Immunotherapy Resistance via CD8<sup>+</sup> T-cell Dysfunction in Clear-Cell Renal Cell Carcinoma Open
Supplementary Figure 4. Flow cytometry gating strategies for SPP1+ TAMs.
View article: Supplementary Figure 9 from SPP1<sup>+</sup> Tumor-Associated Macrophages Drive Immunotherapy Resistance via CD8<sup>+</sup> T-cell Dysfunction in Clear-Cell Renal Cell Carcinoma
Supplementary Figure 9 from SPP1<sup>+</sup> Tumor-Associated Macrophages Drive Immunotherapy Resistance via CD8<sup>+</sup> T-cell Dysfunction in Clear-Cell Renal Cell Carcinoma Open
Supplementary Figure 9. Multivariate analysis of the correlation between SPP1+ TAMs infiltration and OS/RFS among patients with ccRCC in ZSHC cohort.
View article: Supplementary Figure 11 from SPP1<sup>+</sup> Tumor-Associated Macrophages Drive Immunotherapy Resistance via CD8<sup>+</sup> T-cell Dysfunction in Clear-Cell Renal Cell Carcinoma
Supplementary Figure 11 from SPP1<sup>+</sup> Tumor-Associated Macrophages Drive Immunotherapy Resistance via CD8<sup>+</sup> T-cell Dysfunction in Clear-Cell Renal Cell Carcinoma Open
Supplementary Figure 11. Absolute expression of SPP1 in each macrophage cluster.
View article: Supplementary Figure 14 from SPP1<sup>+</sup> Tumor-Associated Macrophages Drive Immunotherapy Resistance via CD8<sup>+</sup> T-cell Dysfunction in Clear-Cell Renal Cell Carcinoma
Supplementary Figure 14 from SPP1<sup>+</sup> Tumor-Associated Macrophages Drive Immunotherapy Resistance via CD8<sup>+</sup> T-cell Dysfunction in Clear-Cell Renal Cell Carcinoma Open
Supplementary Figure 14. Characterization of T cells through CyTOF.
View article: Clinicopathological and molecular correlates of clinical benefit from disitamab vedotin (RC48), a HER-2-targeting antibody-drug conjugate, in metastatic urothelial carcinoma: a multi-center, real-world study
Clinicopathological and molecular correlates of clinical benefit from disitamab vedotin (RC48), a HER-2-targeting antibody-drug conjugate, in metastatic urothelial carcinoma: a multi-center, real-world study Open
In conclusion, patients with higher HER-2 expression, positive responses to chemotherapy, or elevated TMB are more likely to benefit from DV. These discoveries support the rationale for employing HER-2 antibody-drug conjugates (ADCs) for m…
View article: ARID1A Loss plus CD8+ T-Cell Infiltration Associate with Favorable Clinical Outcomes in Urothelial Carcinoma
ARID1A Loss plus CD8+ T-Cell Infiltration Associate with Favorable Clinical Outcomes in Urothelial Carcinoma Open
Purpose: ARID1A, encoding a component of the switch/sucrose nonfermentable complex, is frequently mutated in urothelial carcinoma. However, its specific impacts on clinical outcomes and CD8+ T-cell functions in urothelial carcinoma remain …